Edoxaban affects TRAP-dependent platelet aggregation
| Autor: | Jela Ivankova, Jan Stasko, Juraj Sokol, Marian Mokan, M. Mokan, Frantisek Nehaj |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Platelet Aggregation medicine.drug_mechanism_of_action Platelet aggregation Pyridines Factor Xa Inhibitor 030204 cardiovascular system & hematology Pharmacology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Edoxaban Internal medicine Atrial Fibrillation medicine Humans Platelet Prospective Studies 030212 general & internal medicine Prospective cohort study Aged Aged 80 and over Hematology business.industry Significant difference Atrial fibrillation Middle Aged medicine.disease Stroke Thiazoles chemistry Female Cardiology and Cardiovascular Medicine business Factor Xa Inhibitors |
| Zdroj: | Journal of Thrombosis and Thrombolysis. 49:578-583 |
| ISSN: | 1573-742X 0929-5305 |
| DOI: | 10.1007/s11239-020-02093-9 |
| Popis: | Edoxaban is an oral anticoagulant drug and a direct factor Xa inhibitor. However, it is still not fully understood if and how edoxaban impacts platelet function. This prospective study aimed to assess in vitro platelet function in patients with atrial fibrillation (AF) receiving edoxaban. It was a single centre study quantifying platelet aggregation in 20 patients treated with edoxaban by light transmission aggregometry. The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly lower 2 h after taking edoxaban compared to baseline value (44.7 ± 32.03% vs. 73.3 ± 25.55%; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink